Next Generation Freespira® System for Panic Attacks to be Unveiled at Anxiety and Depression Association of America Conference

Posted On April 4, 2017

Danville, CA – (April 4, 2017) – Palo Alto Health Sciences, Inc. (PAHS), developer of the Freespira® at-home treatment for panic attacks and panic disorder, today announced that the latest generation Freespira System will be debuted at the Anxiety and Depression Association of America’s Annual Conference April 6-9 in San Francisco. Sleeker and more ergonomic, the new Freespira handheld sensor provides quicker start-up and improved ease of use, enhancing the patient’s experience and adherence. As in prior designs, Freespira seamlessly uploads treatment data to a secure server for clinical review and monitoring, which facilitates patient and provider engagement.

Offered under the supervision of a licensed healthcare provider and completed in the convenience and privacy of the patient’s home, the Freespira treatment is both simple and effective. With only two 17-minute breathing sessions a day over a four-week period, 71% of patients in a recently published multi-center clinical trial eliminated panic attacks immediately after treatment. At 12 months post-treatment, 79% of patients were panic attack free.
Palo Alto Health Sciences’ Chief Clinical Officer, Robert Cuyler, PhD, commented, “Patients report high satisfaction with the Freespira System’s ease of use and clinical benefit. Moreover, many Freespira patients report feeling better in only a couple of weeks, which further motivates them to continue the treatment.”
Debra Reisenthel, PAHS President and CEO added, “The latest generation of Freespira demonstrates our ongoing commitment to continued research and product development, as well as our goal to exceed patient and clinician expectations of the Freespira treatment.”

The Cost of Panic
Panic attacks affect an estimated 27 million in the U.S., impacting their lives in profoundly negative ways, including overall quality of life and productivity. Furthermore, panic attacks are often misinterpreted as a serious medical event such as a heart attack, which leads to excess emergency room visits, tests, medication use, and doctor visits. Given the five-fold increase in annual use of healthcare resources by these patients, fewer panic attacks are expected to lead to reduced medical utilization and costs.

About Freespira
Freespira is an FDA-cleared, non-invasive, drug-free, four-week at-home treatment for panic attacks and panic symptoms. Treatment is authorized and completed under the supervision of a licensed healthcare provider. Freespira is clinically proven to reduce or eliminate panic attacks and symptoms of panic disorder, a mental health condition in which debilitating anxiety leads to life-altering avoidance behaviors. Many individuals with panic chronically hyperventilate, even when not experiencing a panic attack. This abnormal breathing pattern has been shown to exacerbate attacks. Freespira works by training the patient to stabilize respiration rate and exhaled carbon dioxide levels, which reduces or eliminates the chronic hyperventilation. A recent multi-center clinical trial demonstrated that at 12 months post-treatment, 79% of treated patients were free of panic attacks and 82% had significant symptom reduction.

About Palo Alto Health Sciences, Inc.
Palo Alto Health Sciences, Inc. is a privately held Silicon Valley digital therapeutic company at the forefront of revolutionizing behavioral healthcare with evidence-based, non-invasive, drug-free solutions. Their first product, Freespira, is an FDA-cleared treatment for individuals suffering from panic disorder, panic attacks and other symptoms of panic. In the United States, over 6.7 million adults annually suffer from panic disorder; panic attacks affect a total of 27 million adults in the U.S. every year and are a common component of other anxiety disorders.
Freespira is commercially available throughout the U.S. and is currently being evaluated by Anthem and Highmark Health in regional Quality Improvement Programs to assess Freespira’s impact in reducing the elevated medical costs of treating patients with panic disorder. To learn more, visit or contact

Michele Kong
(800) 735-8995